















































Residual treatment-resistant cancer cells are thought to 
be the drivers of poor clinical outcomes, in many cancer 
types [1]. These tumor-initiating cells (TICs) or cancer 
stem-like   cells  (CSCs)  are  resistant  to   conventional  
 
 















































therapies, leading to recurrence, metastatic cell 
dissemination and drug-resistance [2-4]. CSCs are 
resistant to cellular stress, and are able to undergo 
anchorage-independent growth, allowing the formation 
of 3D multi-cellular tumor spheroids, that share 
properties with CSCs and progenitor cells [5, 6]. During 
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Abstract: Bedaquiline  (a.k.a.,  Sirturo)  is an anti‐microbial agent, which  is approved by  the  FDA  for  the  treatment of
multi‐drug  resistant  pulmonary  tuberculosis  (TB).    Bedaquiline  is  a  first‐in‐class  diaryl‐quinoline  compound,  that
mechanistically  inhibits  the  bacterial  ATP‐synthase,  and  shows  potent  activity  against  both  drug‐sensitive  and  drug‐
resistant  TB.  Interestingly,  eukaryotic  mitochondria  originally  evolved  from  engulfed  aerobic  bacteria.  Thus,  we
hypothesized  that,  in  mammalian  cells,  bedaquiline  might  also  target  the  mitochondrial  ATP‐synthase,  leading  to
mitochondrial dysfunction and ATP depletion.   Here, we show that bedaquiline has anti‐cancer activity, directed against
Cancer Stem‐like Cells (CSCs). More specifically, we demonstrate that bedaquiline treatment of MCF7 breast cancer cells
inhibits mitochondrial oxygen‐consumption, as well as glycolysis, but  induces oxidative  stress.  Importantly, bedaquiline
significantly blocks the propagation and expansion of MCF7‐derived CSCs, with an  IC‐50 of approx. 1‐μM, as determined
using  the  mammosphere  assay.  Similarly,  bedaquiline  also  reduces  both  the  CD44+/CD24low/‐  CSC  and  ALDH+  CSC
populations,  under  anchorage‐independent  growth  conditions.  In  striking  contrast,  bedaquiline  significantly  increases
oxygen consumption in normal human fibroblasts, consistent with the fact that it is well‐tolerated in patients treated for
TB  infections.    As  such,  future  pre‐clinical  studies  and  human  clinical  trials  in  cancer  patients  may  be  warranted.
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these anchorage-independent conditions, most “bulk” 
epithelial cancer cells undergo cell death, termed 
“anoikis”. Thus, each 3D multi-cellular tumor-sphere is 
formed from the clonal expansion of a single CSC. As 
such, 3D tumor sphere formation enriches for a cell 
population with CSC-like properties [6]. In this context, 
3D tumor spheres (i.e., mammospheres) prepared from 
breast cancer epithelial cell lines are a well-established 
model system.  
 
We and others have recently shown that CSCs are 
critically dependent on mitochondrial function, for their 
successful propagation and clonal expansion [7-11]. In 
fact, during mammosphere formation, five subunits of 
the mitochondrial ATP synthase are significantly up-
regulated (ATP5B, ATP5A1, ATP5F1, ATP5H and 
ATP5O); remarkably, ATP5B was dramatically over-
expressed in MCF7-derived mammospheres, as 
compared with MCF7 monolayer cells [7]. Clinically, 
ATP5B protein levels are also elevated in the serum of 
patients with breast cancer and ATP5B is part of a 21-
protein signature that predicts the development of 
distant metastasis [12].  
 
During our continued search for FDA-approved drugs 
that may behave as mitochondrial inhibitors, we 
identified bedaquiline, an antibiotic that was originally 
developed to block the bacterial ATP-synthase of multi- 
drug resistant pulmonary tuberculosis (TB) [13-15]. 
Because mitochondria originally evolved from bacteria, 
we speculated that bedaquiline might also target the 
mitochondrial ATP-synthase (Complex V), leading to 
ATP depletion.  
 
Here, we propose that bedaquiline could be repurposed 
as a new anti-cancer drug, for the targeting in 
mitochondria within CSCs. More specifically, we show 
that bedaquiline treatment of MCF7 breast cancer cells 
inhibits oxygen-consumption and metabolically induces 
aerobic glycolysis (the Warburg effect), as well as 
oxidative stress. Importantly, bedaquiline blocks the 
propagation of MCF7-derived CSCs, with an IC-50 of 1 
μM, as determined using the mammosphere assay. 
Bedaquiline also targets both CD44+/CD24low/- CSC 
and ALDH+ CSC populations, under anchorage-




Here, we aimed to assess the mitochondrial inhibitory 
effects of bedaquiline (also known as TMC207 and 
R207910). In addition, we tested the hypothesis that 
bedaquiline could be used to inhibit the propagation of 

























Metabolic profiling of MCF7 breast cancer cells 
treated with bedaquiline 
 
First, we investigated the metabolic effects of 
bedaquiline on MCF7 breast cancer cells grown as 
monolayers. Extracellular acidification rates (ECAR) 
and real-time oxygen consumption rates (OCR) for cells 
treated with bedaquiline were assessed using the 
Seahorse Extracellular Flux (XFe-96) analyzer. More 
specifically, OCR is a surrogate marker for OXPHOS 
activity, while ECAR is a measure of glycolysis.  
 
Figure 2 shows that bedaquiline dose dependently 
inhibits oxygen consumption in MCF7 cells, reducing 
respiration, both maximal and basal, as well as ATP 
levels. In addition, bedaquiline inhibited glycolysis in 
MCF7 cells (Figure 3, A-E). Determination of the Cell 
Energy Profile indicated that bedaquiline shifts MCF7 
cells from an energetic to a quiescent state (Figure 3F). 
 
Next, we performed FACS analysis on MCF7 cells 
stained with MitoTracker probes to follow 
mitochondrial mass and membrane potential. Figure 4A 
shows that bedaquiline reduces MitoTracker Orange 
staining, indicative of decreased mitochondrial 
membrane potential. Conversely, Figure 4B shows that 
bedaquiline increases MitoTracker Deep-Red staining, 
reflecting increased mitochondrial mass. Importantly, 
assessing the ratio of mitochondrial membrane potential 
to mass revealed that bedaquiline significantly reduces 
membrane potential per mitochondria (Figure 4C). 
Finally, Reactive Oxygen Species (ROS) levels were 
Figure  1.  Bedaquiline:  Structure  and  Activity.
Bedaquiline, also known as TMC207 and R207910, is a first‐in‐
class diaryl‐quinoline  compound,  that mechanistically  inhibits
the bacterial ATP‐synthase. 
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increased, as assessed by FACS analysis using the CM-
H2DCFDA probe (Figure 4D). In summary, these data 



















































targets mitochondria by inhibiting oxygen consumption 
in human breast cancer cells, driving an increase in 

























































Table  1.    High  ATP5B  mRNA  levels  are  associated  with  decreased  overall 
survival, in both ER(+) and ER(‐) breast cancer patients.  
 
Cancer Subtype HR/OS Log-Rank N 
All Subtypes 1.64 8.3e-05 1,103 
    
ER(+) 1.77 7.4e-05 819 
ER(-)/Basal  2.41 0.019 198 
    
ER(+)/Luminal A 1.63 0.039 500 


















































Metabolic profiling of normal human fibroblasts 
(hTERT-BJ1) treated with bedaquiline 
 
To assess whether bedaquiline also behaves as a 
mitochondrial inhibitor in normal human fibroblasts, we 
examined its metabolic effects on hTERT-BJ1 cells, 
after 48 hours treatment. Interestingly, Figure 5 
demonstrates that bedaquiline augments oxygen 
consumption and ATP levels in normal human 














































analyzer. In addition, bedaquiline also boosts 
glycolysis in normal human fibroblasts, as seen in 
Figure 6. Remarkably, the Cell Energy Profile plot 
(OCR versus ECAR) shows that bedaquiline shifts 
normal human fibroblasts from a quiescent to an 
energetic state (Figure 6F), improving their overall 
metabolic profile. Thus, our results firmly establish 
that bedaquiline specifically inhibits mitochondrial 
respiration in cancer cells, while enhancing mito-












































Bedaquiline significantly inhibits CSC propagation 
and survival 
 
Since bedaquiline behaved as a specific inhibitor of 
mitochondrial respiration in cancer cells, we next 
examined its effects on the behavior of the CSC 
population.  
 
More specifically, MCF7 cells were grown as 
mammospheres and treated with bedaquiline at 
increasing concentrations. Vehicle alone controls were 
processed in parallel. Interestingly, Figure 7A shows 
that bedaquiline halts mammosphere formation in a 
dose-dependent fashion (IC-50  ~1 μM). In addition, 
expression levels of CSC markers (CD24 and CD44) 
were determined. Under these anchorage-independent 
conditions,  bedaquiline  diminished  the  CD44+/CD24- 
low cancer cell population, which are believed to be the 





































Finally, we evaluated the levels of ALDEFLUOR, an 
independent marker of CSCs. ALDEFLUOR was 
measured by FACS analysis.  Figure 7C shows that 
bedaquiline significantly decreases the ALDEFLUOR-
positive cell population. As a negative control, we 
employed DEAB (diethylaminobenzaldehyde), a 
specific ALDH inhibitor (Figure 7D). Thus, these 
results indicate that bedaquiline pre-treatment reduces 
the CSC population, as assessed by three independent 
parameters, namely mammosphere formation, 
CD44/CD24 staining and ALDEFLUOR activity. 
 
Bedaquiline does not affect the viability of the total 
cancer cell population, or normal human fibroblasts 
 
We next determined if bedaquiline targets only the CSC-
population, or if bedaquiline generally reduces the 
survival of the ‘bulk’ MCF7 cancer cell population 
and/or normal human fibroblasts (hTERT-BJ1). Figure 
Figure  4. Bedaquiline reduces mitochondrial membrane potential, with a significant rise in
ROS levels. FACS analysis was carried out on MCF7 cells treated with 10μM bedaquiline for 48 hours.
(A,  B)  Bedaquiline  reduces  mitochondrial  membrane  potential  (MitoTracker  Orange),  with  a  likely
compensatory  increase  in mitochondrial mass  (MitoTracker Deep‐Red).  (C) The  ratio of mitochondrial
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8A shows that bedaquiline treatment had little or no 
effect on MCF7 cell viability, even at a concentration of 
10 μM. Similarly, bedaquiline treatment had no effect on 
the viability of normal human fibroblasts (Figure 8B). In 
summary, our results indicate that bedaquiline 
preferentially inhibits the CSC population (compare 
Figures 7 and 8), relative to the ‘bulk’ cancer cells and 
fibroblasts.  
 
Bedaquiline does not induce a stress response in 
normal human fibroblasts 
 
The increased ROS levels observed in MCF7 cells 
(Figure 4D) after bedaquiline treatment may also induce 
oxidative stress, activating key signaling pathways, such 
as HIF and NFκB transcription factors. Activation of 
these pathways was assessed by employing luciferase 
reporter assays. Figure 9 (A and B) shows that 
bedaquiline treatment did not affect the activation status 
of the NFκB pathway in normal fibroblasts, and it only 
slightly decreased HIF signaling, under these conditions. 
These results indicate that bedaquiline does not induce a 

































Validation of the prognostic value of ATP5B in 
human breast cancer patients, in both ER(+) and 
ER(-) sub-types 
 
Clinically, ATP5B protein levels are elevated in the 
serum of patients with breast cancer and ATP5B is part 
of a 21-protein signature that predicts the development of 
distant metastasis [12]. Here, we further validated the 
prognostic value of ATP5B. More specifically, we 
assessed whether the levels of ATP5B mRNA show any 
prognostic value in human breast cancer patient cohorts, 
with long-term follow-up (approaching 15-20 years). 
Results are summarized in Table 1. High mRNA 
expression levels of ATP5B were clinically associated 
with significantly reduced overall survival. Similar 
results were obtained in both ER(+) and ER(-) patients, 
as well as in ER(+) sub-types (Table 1).  For specific 
Kaplan-Meier (K-M) curves, please see Supplemental 
Figure S1. Thus, we independently confirmed the 
prognostic value of ATP5B, a key subunit of mito-
chondrial complex V. As such, elevated levels of ATP5B 
could possibly be used to identify breast cancer patients 
































for  48 hours.  (A)  The  line  graph of  3  independent  experiments  is  shown.  (B, C, D) Basal  respiration, maximal
respiration, and ATP levels were all increased by bedaquiline treatment of normal fibroblasts. ** p<0.001. 
  
















































Bedaquiline is an FDA-approved anti-microbial drug 
that was developed by Janssen Pharmaceuticals for the 
treatment of multi-drug resistant pulmonary tuber-


















































the end of 2012. Bedaquiline mechanistically inhibits 
the bacterial ATP synthase [13]. Thus, we hypothesized 
that, in cancer cells, bedaquiline might also target the 
mitochondrial ATP-synthase, leading to mitochondrial 
dysfunction and ATP depletion. Here, we explored the 
possibility that bedaquiline could be repurposed for 
Figure 6. Bedaquiline augments glycolysis in normal human fibroblasts. The Seahorse XF96 analyzer
was  employed  to  determine  the  status  of  glycolysis  in  normal  human  fibroblasts  treated  with  10μM




www.impactaging.com                      7                                           AGING, June 2016, Vol. 8 No.6
targeting mitochondrial complex V in breast cancer cells. 
To test this hypothesis, we determined its metabolic 
effects on MCF7 cells, using the Seahorse XF-e96, to 
measure mitochondrial function and glycolysis. Our 
results demonstrate that bedaquiline dramatically inhibits 
oxygen consumption and ATP production in the low 
micromolar range. In addition, bedaquiline treatment also 
reduced aerobic glycolysis (a.k.a., the Warburg effect). In 
this context, bedaquiline reduced mitochondrial 
membrane potential, but increased mitochondrial mass 
and overall ROS production. Most importantly, 
bedaquiline potently inhibited the propagation of CSCs, 
with an IC-50 of 1 μM, as measured using the 
mammosphere assay. Remarkably, bedaquiline treatment 
increased mitochondrial respiratory function, ATP 
production, and glycolysis in normal human fibroblasts. 
Thus, these results provide clear evidence that 
bedaquiline specifically inhibits mitochondrial respiration 
in MCF7 cancer cells, but not in normal human 
fibroblasts. As such, our new findings suggest that 
bedaquiline could be used to target the mitochondrial 
F0F1-ATPase/ATP synthase in CSCs.  
 
Consistent with our current findings, we have 































bitor of the mitochondrial ATP-synthase (complex V), 
effectively targets MCF7-derived CSCs with an IC-50 
of 100 nM [7]. However, oligomycin (another 
antibiotic) in not FDA-approved, and is considered to 
be both a bacterial and mitochondrial “poison”, that is 
too toxic for safe use in humans or animals.  
 
Interestingly, only one previous study showed that 
TMC207 (now known as bedaquiline) had little or no 
effect on ATP production in a human ovarian cancer 
cell line, namely OVCAR3 cells, with an IC-50 > 200 
μM [16]. However, no other cancer cell lines were 
studied. Similarly to our results, bedaquiline had 
minimal inhibitory activity on oxygen consumption in 
mouse liver and bovine heart mitochondria. The authors 
thus suggested that the inhibitory effects of bedaquiline 
were restricted to mycobacterium. Importantly, the 
effects of bedaquiline on cancer stem-like cells were not 
evaluated [16]. It has been suggested that bedaquiline 
binds to the subunit C of the mycobacterial ATP 
synthase, based on computational modeling [17]. This 
corresponds to the three human genes, namely 
ATP5G1, ATP5G2, ATP5G3, which differ only in their 
mitochondrial import sequence, but not in the sequence 
































Figure  7.  Bedaquiline  halts  the  propagation  of  the  CSC  population.  (A) MCF7  cells were  grown  as
mammospheres,  and  treated  with  bedaquiline  at  increasing  concentrations  or  vehicle  alone.  Note  that
bedaquiline  inhibits mammosphere formation efficiency (MFE),  in a dose‐dependent fashion, with an  IC‐50 of
~1  μM.  *  p<0.05,  **  p<  0.01,  evaluated  by  Student’s  t  test.  (B) MCF7  cell monolayers were  treated with























































Interestingly, several natural products, especially 
polyphenolic phytochemicals [18], also act as 
inhibitors of the F0F1-ATPase/ATP synthase 
(Complex V), that is present within the inner 



















































the following compounds, listed in rank order of their 
potency:  piceatannol > resveratrol  > epigallocatechin-
gallate >epicatechin-gallate/curcumin > genistein/bio- 
chanin  A/ quercetin / kaempferol / morin > phloretin/ 
apigenin/daidzein.  
Figure  7.  Bedaquiline  halts  the  propagation  of  the
CSC population.  (C, D) Similar  results were also obtained
using  ALDEFLOUR  as  a  marker  of  CSCs.  ALDEFLUOR  was
measured  by  FACS  analysis.  DEAB  (diethylaminobenzal‐





























































































































Figure  10.  Structure  of  trans‐Piceatannol  and  trans‐Resveratrol.  (A)  Interestingly,  these
polyphenolic  phytochemicals  act  as  inhibitors  of  the  F0F1‐ATPase/ATP  synthase  (Complex V),  that  is
present  within  the  inner  membrane  of  eukaryotic  mitochondria.  These  compounds  have  been






































The structures of some of these compounds are 
highlighted in Figure 10A.  Many of these flavonoid 
compounds have been suggested to act as either anti-
cancer agents or as compounds that have anti-aging 
properties, consistent with their effects of reducing or 
“fine-tuning” mitochondrial function [18, 19].  
 
Interestingly, Figure 10B shows that the structural 
backbone of trans-piceatannol and trans-resveratrol is 
actually embedded within bedaquiline. These common 
structural similarities within the bedaquiline molecule 
are specifically highlighted in orange. In fact, trans-
piceatannol and trans-resveratrol also functionally 
demonstrate anti-bacterial properties, behaving as 
antibiotics [19]. 
 
Our overall approach to drug repurposing is briefly 
summarized in Figure 11. Thus far, we have identified 
six different classes of FDA-approved antibiotics that 
could be used to therapeutically target mitochondria 



































mechanism(s) of selectivity that allows the inhibitory 
effects of bedaquiline to be seen preferentially at the 
level of the CSC, but not in normal fibroblasts and to a 
lesser extend in mature cancer cells.  One possibility is 
that the mitochondrial ATPase (Complex V) in cancer 
cells and CSCs undergoes a conformational change, so 
that its 3-D structure more closely resembles the ancient 
bacterial ATPase.  This hypothesis deserves further 
investigation.  
 
MATERIALS AND METHODS 
 
Materials. MCF7 breast cancer cell lines were 
purchased from the ATCC. Human immortalized 
fibroblasts (hTERT-BJ1) were originally purchased 
from Clontech, Inc. Cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 
10% FBS (fetal bovine serum), 2 mM GlutaMAX, and 
1% Pen-Strep in a 37°C humidified atmosphere 
containing 5% CO2, unless otherwise noted. Gibco-
brand cell culture media (DMEM/F12) was purchased 
 
Figure 11. Summary: Overall  strategy  for  repurposing FDA‐approved antibiotics as anti‐
cancer  agents  for  targeting  mitochondria  in  CSCs.  Here,  show  that  bedaquiline,  an  FDA‐
approved  antibiotic,  effectively  prevents  the  propagation  of  CSCs,  by  targeting  oxidative
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from Life Technologies. Bedaquiline was purchased 
from AdooQ Bioscience.  
 
Seahorse XFe-96 metabolic flux analysis. Extracellular 
acidification rates (ECAR) and real-time oxygen 
consumption rates (OCR) for cells treated with 
bedaquiline were assessed using the Seahorse 
Extracellular Flux (XFe-96) analyzer (Seahorse 
Bioscience, MA, USA) [20]. 10,000 cells per well were 
seeded into XFe-96 well cell culture plates, and 
incubated overnight to allow attachment. Cells were 
then treated with bedaquiline (1μM or 10 μM) for 48 
hours. Vehicle alone (DMSO) control cells were 
processed in parallel. After 48 hours of incubation, cells 
were washed in pre-warmed XF assay media (or for 
OCR measurement, XF assay media supplemented with 
10mM glucose, 1mM Pyruvate, 2mM L-glutamine and 
adjusted at 7.4 pH). Cells were then maintained in 175 
µL/well of XF assay media at 37°C, in a non-CO2 
incubator for 1 hour. During the incubation time, we 
loaded 25 µL of 80mM glucose, 9µM oligomycin, and 
1M 2-deoxyglucose (for ECAR measurement) or 10µM 
oligomycin, 9µM FCCP, 10µM rotenone, 10µM 
antimycin A (for OCR measurement), in XF assay 
media into the injection ports in the XFe-96 sensor 
cartridge. Measurements were normalized by protein 
content (Bradford assay). Data set was analyzed by 
XFe-96 software and GraphPad Prism software, using 
one-way ANOVA and Student’s t-test calculations. All 
experiments were performed in quintuplicate, three 
times independently. Energy plots, shown in Figures 3F 
and 6F, were generated by following the manufacturer’s 
guidelines and instructions (Seahorse, Inc.).  
 
Mitochondrial staining. Mitochondrial activity was 
assessed with MitoTracker Orange (#M7510, 
Invitrogen), whose accumulation in mitochondria is 
dependent upon membrane potential. Mitochondrial 
mass was determined using MitoTracker Deep-Red 
(#M22426, Invitrogen), localizing to mitochondria 
regardless of mitochondrial membrane potential. MCF7 
cells were treated with 10 μM bedaquiline for 48 hours. 
Vehicle alone (DMSO) control cells were processed in 
parallel. After 48 hours, cells were incubated with pre-
warmed MitoTracker staining solution (diluted in 
PBS/CM to a final concentration of 10 nM) for 30-60 
minutes at 37°C. All subsequent steps were performed 
in the dark. Cells were washed in PBS, harvested, and 
re-suspended in 300 μL of PBS/CM. Cells were then 
analyzed by flow cytometry. Data analysis was 
performed using FlowJo software. 
 
ROS staining. Reactive oxygen species (ROS) 
production was measured using CM-H2DCFDA 
(C6827, Invitrogen), a cell-permeable probe that is non-
fluorescent until oxidation within the cell. MCF7 cells 
were treated with 10μM bedaquiline for 48 hours. 
Vehicle alone (DMSO) control cells were processed in 
parallel. After 48 hours, cells were washed with PBS, 
and incubated with CM-H2DCFDA (diluted in PBS/CM 
to a final concentration of 1 μM) for 20 minutes at 
37°C. All subsequent steps were performed in the dark. 
Cells were rinsed, harvested, and re-suspended in 
PBS/CM. Cells were then analyzed by flow cytometry 
using the Fortessa (BD Bioscience). ROS levels were 
estimated by using the mean fluorescent intensity of the 
viable cell population. The results were analyzed using 
FlowJo software (Tree star Inc.).  
 
Mammosphere culture. A single cell suspension was 
prepared using enzymatic (1x Trypsin-EDTA, Sigma 
Aldrich, #T3924), and manual disaggregation (25 gauge 
needle) to create a single cell suspension [6]. Cells were 
plated at a density of 500 cells/cm2 in mammosphere 
medium (DMEM-F12/B27/20ng/ml EGF/PenStrep) in 
non-adherent conditions, in culture dishes coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932). Then, cells were treated with increasing 
concentrations of bedaquiline (range 1 μM to 25 μM). 
Vehicle alone (DMSO) control cells were processed in 
parallel. Cells were grown for 5 days and maintained in 
a humidified incubator at 37°C. After 5 days for culture, 
spheres >50 μm were counted using an eye piece 
graticule, and the percentage of cells plated which 
formed spheres was calculated and is referred to as 
percentage mammosphere formation, and was 
normalized to one (1 = 100 %MFE). Similar results 
were also obtained when cells were seeded at a density 
of 200 cells/cm2. 
 
CD44/CD24 analysis. 1 x 105 MCF7 cells were treated 
with bedaquiline (5 μM and 10 μM) for 48 hours in 6-
well plates, grown as a monolayer. Then, cells were 
trypsinized and seeded in low-attachment plates in 
mammosphere media. After 12 hours, MCF7 cells were 
spun down and incubated with CD24 (IOTest CD24-PE, 
Beckman Coulter) and CD44 (APC mouse Anti-Human 
CD44, BD Pharmingen cat.559942) antibodies for 15 
minutes on ice. Cells were rinsed twice and incubated 
with LIVE/DEAD dye (Fixable Dead Violet reactive 
dye; Invitrogen) for 10 minutes. Samples were then 
analyzed by FACS (Fortessa, BD Bioscence). Only the 
live population, as identified by the LIVE/DEAD dye 
staining, was analyzed for CD24/CD44 expression. 
Data were analyzed using FlowJo software.  
 
SRB assay. Cell viability was assessed by 
sulphorhodamine (SRB) assay, based on the 
measurement of cellular protein content. After treatment 
with bedaquiline (5μM and 10 μM) for 5 days in 96 
  
www.impactaging.com                     12                                          AGING, June 2016, Vol. 8 No.6
well plates, cells were fixed with 10% trichloroacetic 
acid (TCA) for 1 hour in cold room, and dried overnight 
at room temperature. Then, cells were incubated with 
SRB for 15 min, washed twice with 1% acetic acid, and 
air dried for at least 1 hour. Finally, the protein-bound 
dye was dissolved in 10 mM Tris pH 8.8 solution and 
read using a plate reader at 540 nm. 
 
Evaluation of HIF and NFκB signaling pathways. The 
Cignal Lenti reporter assay (Luc) system (Qiagen) was 
chosen for monitoring HIF- and NFκB-Luc pathway 
activity in fibroblasts, as we previously described [21] 
[22]. Luciferase assay (E1501, Promega) was performed 
in luciferase reporter hTERT-BJ1 cells treated with 
bedaquiline. Briefly, 1 × 104 hTERT-BJ1 reporter cells 
were seeded in black-walled 96-well plates and then 
were treated with 10 μM bedaquiline for 48 hours. 
Vehicle alone (DMSO) control cells were run in 
parallel. Three replicates were used for each condition. 
After 48 hours, luciferase assay was performed 
according to the manufacturer’s instructions. Light 
signal was acquired for 2 minutes in photons/second in 
the Xenogen VivoVision IVIS Lumina (Caliper Life 
Sciences), and the results were analyzed using the 
Living Image 3.2 sofware (Caliper Life Sciences). 
Luminescence was normalized using SRB (total 
proteins), as a measure of cell viability. 
 
Statistical analysis. Data is represented as the mean ± 
standard error of the mean (SEM), taken over ≥ 3 
independent experiments, with ≥ 3 technical replicates 
per experiment, unless otherwise stated. Statistical 
significance was measured using the analysis of 
variance (ANOVA) test or student t-test. P ≤ 0.05 was 
considered significant and all statistical tests were two-
sided.  
 
Validating the prognostic value of ATP5B. We used an 
open-access online survival analysis tool to interrogate 
publically available microarray data from up to 1,103 
breast cancer patients [23]. Hazard-ratios were 
calculated, at the best auto-selected cut-off, and p-
values were calculated using the logrank test and plotted 
in R. K-M curves were generated online using the K-M-
plotter (as high-resolution TIFF files), using univariate 
analysis: http://kmplot.com/analysis/index.php?p= 
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Supplementary Figure S1. K‐M plots of OS (Overall Survival) are shown for ATP5B expression in different sub‐groups of
breast cancer patients (Panesls A‐E). 
